Skip to main
TMDX
TMDX logo

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. demonstrated strong financial performance with an impressive operating margin expansion of 910 basis points year-over-year in 2024, followed by an additional 950 basis points increase in the first half of 2025. The company capitalized on a growing transplant market, as evidenced by a 7.3% increase in liver, heart, and lung transplants in the U.S. from 2023 to 2024, which correlates with a significant uptick in logistics revenue due to increased aviation activity and overall market share growth. Furthermore, expectations of meaningful earnings per share upside are supported by anticipated new product launches and favorable trends in international growth and organ transplant adoption rates.

Bears say

TransMedics Group Inc faces significant challenges that may adversely impact its financial outlook, including the disappointing adoption rates of its Organ Care System (OCS) for lung transplants and increasing competition, which could lead to market share loss and pricing pressures. Additionally, a reported 13% decline in aviation flight volumes and hours could translate into a substantial revenue decrease of approximately $25.9 million, compounded by the risks associated with the firm's ability to effectively scale its salesforce and penetrate new medical centers. Lastly, the company's current valuation, trading at an NTM EV/sales of 6.4x—40% below its five-year average of 10.7x—further indicates investor skepticism regarding its future growth prospects amidst these operational and market challenges.

TMDX has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 11 analysts, TMDX has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $130.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $130.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.